Edition:
India

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

10,050JPY
16 Nov 2018
Change (% chg)

¥62 (+0.62%)
Prev Close
¥9,988
Open
¥10,150
Day's High
¥10,250
Day's Low
¥10,015
Volume
553,200
Avg. Vol
1,298,126
52-wk High
¥11,490
52-wk Low
¥5,402

Select another date:

Thu, Oct 25 2018

Photo

Eisai, Biogen Alzheimer's data fails to convince skeptics

Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 2-Eisai, Biogen Alzheimer's data fails to convince skeptics

Oct 25 Eisai Co Ltd and partner Biogen Inc said on Thursday that the highest dose of their experimental Alzheimer's disease drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data and Biogen shares fell about 2 percent.

UPDATE 1-Biogen shares slip after Alzheimer's data fails to convince

Oct 25 Biogen Inc and partner Eisai Co Ltd said on Thursday the highest dose of its experimental Alzheimer's drug showed effectiveness in a new analysis, but investors remained skeptical about the reliability of the data.

Biogen/Eisai Alzheimer's data suggests treatment effect related to drug

Oct 25 Biogen and partner Eisai Co Ltd said data from their experimental Alzheimer's drug suggested that the treatment effect for the highest dose was related to the drug, and not to an imbalance of patients in the treatment groups.

Nikkei rises as weak yen helps mood; Eisai soars

TOKYO, Aug 24 Japan's Nikkei rose on Friday as a weaker yen supported sentiment, with the pharmaceutical sector leading gains after a report that Eisai moved forward its mid-term profit goal by one year.

Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

(This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970)

Japan's Eisai gains U.S. approval for liver cancer treatment

Aug 16 The U.S. Food and Drug Administration on Thursday approved https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm617185.htm a therapy by Japan's Eisai Co Ltd for previously untreated patients with a common form of liver cancer.

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Biogen, Eisai's Alzheimer's drug succeeds in mid-stage trial, shares soar

Japanese drugmaker Eisai Co and Biogen Inc said that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose. | Video

Select another date: